financetom
Business
financetom
/
Business
/
BRIEF-DSV Signs Agreement To Acquire Schenker
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BRIEF-DSV Signs Agreement To Acquire Schenker
Sep 14, 2024 5:53 AM

Sept 13 (Reuters) - DSV A/S ( DSDVF ):

* DSV SIGNS AGREEMENT TO ACQUIRE SCHENKER

* DSV, 1132 - DSV SIGNS AGREEMENT TO ACQUIRE SCHENKER

* TRANSACTION VALUES SCHENKER AT EUR 14.3 BILLION

(APPROXIMATELY

DKK 107 BILLION)

* TOGETHER, DSV AND SCHENKER WILL HAVE A COMBINED REVENUE OF

DKK

293 BILLION

* SIGNED AN AGREEMENT WITH DEUTSCHE BAHN TO ACQUIRE 100% OF

SCHENKER AG

* TRANSACTION EXPECTED TO COMPLETE IN Q2 2025

* DISCONTINUES DKK 1.5 BILLION SHARE BUYBACK PROGRAMME

* EXPECTS TO FINANCE TRANSACTION DURING NEXT 12 MONTHS

THROUGH A

COMBINATION OF EQUITY FINANCING OF AROUND EUR 4-5 BILLION AND

DEBT FINANCING

* TO ACQUIRE 100% OF SCHENKER AG IN ALL-CASH DEAL

* TRANSACTION IS EXPECTED TO BE EPS ACCRETIVE IN YEAR 2

AFTER

CLOSING OF TRANSACTION

* TRANSACTION IS NOT EXPECTED TO HAVE AN IMPACT ON DSV'S

RESULTS

IN 2024

* 2024 GUIDANCE REMAINS UNCHANGED

Source text for Eikon:

Further company coverage:

(Gdansk Newsroom)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Novavax Says FDA Review Target Date Set for Covid-19 Vaccine Biologics License Application
Novavax Says FDA Review Target Date Set for Covid-19 Vaccine Biologics License Application
Jun 6, 2024
12:26 PM EDT, 06/06/2024 (MT Newswires) -- Novavax ( NVAX ) said Thursday that the US Food and Drug Administration has completed the filing review of the company's biologics license application for its Covid-19 vaccine and set a review target date of April 2025. As a result, the company said commercial sales of its Covid-19 vaccine during the 2024 to...
Arch Capital Group's Focus on Core Tenets Ensures Solid Path to Profitability, Morgan Stanley Says
Arch Capital Group's Focus on Core Tenets Ensures Solid Path to Profitability, Morgan Stanley Says
Jun 6, 2024
12:32 PM EDT, 06/06/2024 (MT Newswires) -- Arch Capital Group ( ACGL ) is on a solid long-term path to growth and profitability amid its focus on core tenets such as disciplined underwriting, prudent approach to risk, and diversification, Morgan Stanley said in report Thursday. Although hurricane season will serve as an important near term catalyst for most Bermuda based...
Halozyme Therapeutics +13% On Thursday: What's Going On?
Halozyme Therapeutics +13% On Thursday: What's Going On?
Jun 6, 2024
Halozyme Therapeutics, Inc. ( HALO ) shares are trading higher on the bourses on Thursday after it raised its FY24 guidance. The company sees full-year 2024 total revenue of $935 million to $1.015 billion versus $947.33 million estimate (prior view: $915 million to $985 million), representing growth of 13% to 22% over 2023. The company projected revenue from royalties of $520 million to $555 million (prior...
AI Startup Humane Reportedly in Talks With HP, Others for Potential Sale
AI Startup Humane Reportedly in Talks With HP, Others for Potential Sale
Jun 6, 2024
12:30 PM EDT, 06/06/2024 (MT Newswires) -- HP (HPQ) is among the parties artificial intelligence startup Humane is currently in talks with for a potential sale, according to media reports Thursday. The maker of AI Pin, backed by Microsoft (MSFT) among others, has reportedly hired investment bank Tidal Partners to advise on a potential deal. Apart from HP, the company...
Copyright 2023-2026 - www.financetom.com All Rights Reserved